IMMU-70

IMMU-70 (CAR.mNb T cells) is an experimental multispecific CAR-T cell therapy developed by researchers at Northwestern University for the treatment of glioblastoma (GBM). The therapy consists of T cells engineered with a chimeric antigen receptor (CAR) targeting interleukin-13 receptor alpha 2 (IL13Rα2). To address antigen heterogeneity and the immunosuppressive tumor microenvironment, these cells are further engineered to simultaneously secrete a multispecific nanobody (mNb) that targets EGFR, EGFRvIII, and CD16a. This dual-function approach allows the CAR-T cells to directly kill IL13Rα2-positive tumor cells while the secreted nanobody engages CD16a-expressing natural killer (NK) cells and tumor-associated macrophages (TAMs) to target EGFR/EGFRvIII-positive cells and promote phagocytosis, providing a strategy to overcome antigen escape and immunosuppression in GBM.

Other names

IL13Rα2-directed CAR T cells secreting multispecific nanobodyIL13Rα2 CAR-T cells secreting EGFR/EGFRvIII/CD16a nanobody